Mesenchymal Stem Cells in Central Nervous System injury2017

Intrathecal Injection of Mesenchymal Stem Cells in Central Nervous System injury2017

Status

UNKNOWN

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03291366

Enrollment

Registered

2017-09-25

Start date

2017-01-31

Completion date

2022-01-31

Last updated

2017-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Nervous System Injury

Brief summary

Central nervous system (CNS) injury leads to morbidity in patients, which has few good rehabilitation measures. Mesenchymal stem cells seem to have regenerative and tissue-repairing capabilities. The investigators design this study to infuse mesenchymal stem cells (MSCs) intrathecally to CNS injury patients, and observe the safety and efficacy by recording the change of nervous system scores, trying to prove the effect of MSC in rehabilitate CNS injury.

Interventions

DRUGUCMSCC

infusion of aUCMSC and conventional therapy

DRUGconventional treatment

conventional treatment

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* CNS injury \> 3 months * age \> 18 years * willing to give consent * stable vital signs * absence of active infectcion

Exclusion criteria

* any contradiction to intrathecal infusion * age \< 18 years * CNS injury \< 3 months * CNS injury \> 3 years

Design outcomes

Primary

Measure	Time frame
life quality score	1y

Secondary

Measure	Time frame
adverse events	1y

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026